Compound library / Fat Loss / GLP-1
One of the earliest GLP-1 receptor agonists, derived from a compound in Gila monster venom; FDA-approved for type 2 diabetes.
| Category | Fat Loss / GLP-1 |
|---|---|
| Typical route | Subcutaneous |
| Half-life | ~2.4 hours (immediate-release); weeks for extended-release |
| Common dose range | 5-10 mcg twice daily (Byetta) or 2 mg once weekly (Bydureon) |
| Typical cycle length | Ongoing under medical supervision |
BioHack Track models Exenatide (Byetta/Bydureon) at a half-life of 2.4 hours, so every dose you log is decayed against that curve and the app shows what is still circulating — not just what you typed.
Supplied pre-filled; extended-release requires mixing powder with diluent immediately before injecting.
Refrigerate pens; some stable at room temperature short-term per label.
Prescription medication. GI side effects common; same pancreatitis and thyroid C-cell warnings as other GLP-1 drugs.
Track Exenatide (Byetta/Bydureon) in BioHack Track. Half-life, dose range and route come pre-filled from this library — log a dose and the app counts your vial down, models what is in your system, and puts it on the same chart as your labs and body composition.
These open a search of each database for Exenatide (Byetta/Bydureon) — they are not citations, and nothing here is evidence for any particular dose. The same links are in the app.
General reference compiled for use inside the app, not medical advice and not a recommendation to take anything. Dose ranges are what is commonly discussed, not a prescription. Talk to a qualified healthcare professional.